Strong Q1 execution, specialty launch, guidance held on base comparisons

Delivered ₹240 Cr, +24.3% YoY growth confirmed

Delivered ₹51.3 Cr, 21.0% margin (51.3/240), +34.1% YoY

Delivered 32.2% operating margin

Consolidated 24.3%, pathology segments performing above average — ratios consistent

Q1 delivered 24.3% (top end of range). Guidance not upgraded despite beat — reflects caution on Q2-Q4 comps

Commercial launch in Q1 FY27 (vs. prior signal Q4 FY26). Allergy + genomics live; <1% revenue. Multi-year ramp.

900 added in Q1 (vs. ~250-350 typical). Doubled field team (35-40 → ~70). Brand ambassador (Madhuri Dixit) driving recruitment. Expect 500-700/qtr net.

Opened 3 new labs (Muzaffarpur, Kurnool, Prayagraj) in Q1. Total now 44 (43 India + 1 Tanzania). Aiming density in Tier 3-4 markets.

Board approved pursuit of strategic buyer for Nuclear Healthcare. 6-month timeline. Returns <2% on invested capital. Management de-prioritizing.

Held at 'mid to high teens' (15-20%) despite Q1 beat of 24%. MD cited high base comps (Q1 FY26 ₹180 Cr, Q2 ₹200 Cr). Cautious posture.

Peers at 15-20% of portfolio in 3-5yr — our ambition same. Most capex done (Mumbai, Delhi centralized labs). Minimal next year unless volumes explode.

Board approved. Seeking strategic buyer. Expect 6-month process. No definitive buyer yet. Business not growing, low ROC vs pathology.

Tests per patient increasing (vial stays same). Discounting incremental tests to drive comprehensive panels. Volume strong, value per test lower.

Removed calculated parameters (unbilled) from volume. Added many new calculated params (6m). Restatement for clarity, minimal historical variance.

Expect 500-700/qtr net (700+500+500, Q3 lower seasonally). Brand ambassador + field team driving upside. 1,700-2,000 gross possible.

Q1 FY26 base ₹180 Cr, Q2 ₹200 Cr — very high comps. Too early to revise. Hold mid-teens. Will review after H1.

Not specialty (<1%). Mix shift: thyroid (was 20%) → 'semi-specialized' (lipid, markers, PCR). More advanced tests. This is in realization growth.

API IPO rumors unfounded. Debt down ₹1,700 Cr → ₹1,050 Cr. IPO when profitable ex-Thyrocare + debt free (~12 months). No dividend guidance.

Affordability is mission. NIPT priced <50% vs. peers. Aiming volume capture. If volumes materialize, margins comparable to preventive.

'Zero year' for specialty. Too early for targets. Team on ground doing scientific engagement, one-on-one calls. No specific numbers.

Thyrocare branded, not backward integration. Strategy finalized internally. Announcement by September. Will be pleased.

Doubled from ~35-40 to ~70 over the year. Team on ground recruiting, visiting franchisees.

Maintained despite 24.3% Q1 beat. MD cites high Q2-Q4 FY26 comparisons (Q1 ₹180 Cr, Q2 ₹200 Cr). Conservative posture. No upgrade post-beat.

Peer benchmark. Unquantified capex. Immaterial to FY27. Ramp depends on clinical adoption, doc engagement.

Delivered 32.2% Q1 (consolidated). Reinvesting operating leverage into growth (field, specialty, phlebotomy). Infrastructure supports scale.

Dependent on reaching 15-20% scale. Currently <1%, immaterial. No near-term margin dilution expected if volumes modest.

Central processing labs (Mumbai, Delhi) already equipped. Expansion capex only if volumes spike. No major CAPEX burden for specialty.

Q1 beat guidance (24% vs mid-teens). Q2 FY26 base ₹200 Cr (high). Expected deceleration to 15-20% range H2. Risks: competitive pricing, market saturation in Tier 1-2.

Specialty diagnostics is 'zero year'. <1% revenue. Prescription-driven (vs. OTC-heavy preventive). Physician engagement immature. If adoption slow, ramp delayed; margins may dilute if priced low (NIPT at 50% discount).

900 added in Q1 (vs. ~250-350 typical). Brand ambassador + field doubling drove this. MD explicitly flagged: 'not all 900 may stay by year-end.' Implies 100-150 churn/attrition expected. Net addition target 1,700 assumes churn; miss here tanks FY27 guidance.

Nuclear Healthcare + Pulse Hitech: ₹1.72 Cr Q1 PAT (~₹6 Cr annualized) on ₹140 Cr invested = 4% annual ROI (vs. pathology 30%+). Divestment process 6 months. If delayed or buyer offer weak, dilutes consolidated returns and management attention.

API Group debt ₹1,050 Cr (down from ₹1,700 Cr). Promoter stake 100% pledged to lenders. IPO target ~12 months (when profitable ex-Thyrocare + debt free). If refinancing stress or market downturn, may constrain Thyrocare capex or force dividend cuts.

Franchisee revenue per vial up 7% Q1 (vs. flat prior). But driven by mix away from low-margin Aarogyam (21% growth) to semi-specialty (higher value). Over multi-quarter horizon, if Aarogyam growth decelerates further, blended realization could stagnate.